Castle Connolly Top Doctor
Westerville Sleep Center Mahmoud Qadoom, MD · Sleep & Pulmonary Medicine (614) 898-9340

Sleep apnea

Does sleep apnea go away on its own?

Mahmoud Qadoom, MD 6 min read

Typographic title card for Does sleep apnea go away on its own?

Adult obstructive sleep apnea rarely vanishes on its own. The American Academy of Sleep Medicine’s 2019 PAP guideline calls OSA a chronic disease that rarely resolves except with substantial weight loss or successful corrective surgery. Weight change, certain operations, and childhood adenotonsillectomy are real exceptions. They are exceptions, not a promise that the airway will reopen if you wait. Treatment lowers the apnea-hypopnea index. It does not reliably drive that number to zero, including after tirzepatide in the SURMOUNT-OSA trials.

Does adult obstructive apnea just burn out?

No. The Patil 2019 AASM clinical practice guideline on PAP for adult OSA is written on the assumption that you are managing a long-term condition. The good-practice statements require an objective diagnosis before PAP and adequate follow-up after it starts. Buried in that follow-up language is the natural-history sentence clinicians actually use: OSA rarely resolves except with substantial weight loss or successful corrective surgery. Periodic follow-up exists because the disease usually stays.

That is a different claim from “you will always need the same pressure.” Weight, alcohol, supine sleep, nasal congestion, and sedating medicines can change night-to-night severity. The underlying tendency of the pharynx to collapse in sleep is what seldom disappears in an adult who has already met diagnostic criteria. People who feel better after a vacation, a cold resolving, or a few pounds off sometimes conclude the diagnosis was a one-off. Feeling less sleepy is not the same as an AHI below 5 on a repeat study.

The AASM diagnostic guideline (Kapur 2017) is the other half of this. Questionnaires do not diagnose OSA. A normal week of energy after you start sleeping longer does not retire a prior sleep study. If someone has told you the problem will “run its course,” ask them what study they are waiting to repeat, and when.

Can weight loss make it go away?

Weight and AHI move together. They do not move one-for-one to a cure. Peppard, Young, and colleagues followed 690 employed Wisconsin adults with two laboratory studies about four years apart. Relative to stable weight, a 10 percent weight gain predicted about a 32 percent increase in AHI (95 percent CI 20 to 45 percent). A 10 percent weight loss predicted about a 26 percent decrease (95 percent CI 18 to 34 percent). A 10 percent weight gain predicted a six-fold increase in the odds of developing moderate-to-severe disease, defined there as AHI of 15 or more.

Read those percentages as they were written. A 26 percent drop in AHI is meaningful. If your AHI is 40, a 26 percent reduction still leaves you in a range most labs would call moderate or severe. The Wisconsin analysis is a population average, not a guarantee for one neck and one tongue. Baseline BMI itself predicted AHI change independent of the weight change. Anatomy is not only adipose tissue.

That is why this clinic talks about weight as a modifier of sleep apnea, not as a substitute for a treatment plan. If you lose a large amount of weight, a repeat study can show whether residual obstruction still needs PAP, an oral appliance, or something else. Stopping therapy because the scale moved, without a new study, is a guess.

Does Zepbound make the AHI zero?

No. Tirzepatide (Zepbound) received an FDA indication in December 2024 to treat moderate to severe OSA in adults with obesity, in combination with a reduced-calorie diet and increased physical activity. The label does not present the drug as a replacement for PAP. SURMOUNT-OSA, published in the New England Journal of Medicine, ran two 52-week randomized trials: one in people not on PAP, one in people on PAP. Diet and activity counseling went to every participant.

Mean baseline AHI was 51.5 events per hour in the non-PAP study and 49.5 in the PAP study. Least-squares mean AHI change with tirzepatide was −25.3 per hour without PAP and −29.3 per hour with PAP, versus about −5 per hour on placebo. Those are large reductions. Subtracting a 25-event drop from a baseline near 50 still leaves a mean residual AHI far from zero. The trials also reported a composite of “remission or mild non-symptomatic OSA” (AHI under 5, or AHI 5 to 14 with Epworth score of 10 or less) in 42.2 percent of the non-PAP tirzepatide arm and 50.2 percent of the PAP tirzepatide arm, versus 15.9 and 14.3 percent on placebo. Roughly half of treated participants did not meet even that composite. The prescribing information states the trials did not evaluate when or whether PAP should be stopped in people who had been using it.

If you are considering Zepbound for OSA, the honest pitch is: the drug plus diet and activity can lower AHI and body weight in the labeled population. It is not a cure, and it is not an automatic off-ramp from PAP. A follow-up study is how you find out what is left.

What about surgery in adults?

Patil’s “successful corrective surgery” clause is real and narrow. Operations that enlarge or stabilize the airway (tonsillectomy in an adult with large tonsils, selected skeletal procedures, hypoglossal nerve stimulation in people who qualify) can drop AHI. “Successful” is the word that does the work. Published surgical series report residual obstruction in a substantial fraction of patients. A postoperative sleep study is how success is defined, not how the recovery felt.

Uvulopalatopharyngoplasty in particular has a long history of incomplete response. If a surgeon told you the snoring would end and therefore the apnea would end, that is a snoring claim. Apnea is scored from airflow, effort, and oxygen or arousals, not from how quiet the bedroom became.

Nerve-stimulation and other CPAP alternatives are treatments you live with, the way you live with PAP. An implant that is turned off at 90 days is not a cure. It is an untreated airway again.

Is childhood apnea a different story?

Often, yes, which is why adult advice should not be copied onto a seven-year-old. The Childhood Adenotonsillectomy Trial randomized children 5 to 9 years old with obstructive sleep apnea syndrome, without prolonged desaturation, to early adenotonsillectomy or watchful waiting. Normalization, defined as AHI under 2 and obstructive apnea index under 1, was more common after early surgery than after watchful waiting (79 percent versus 46 percent) at about 7 months.

The watchful-waiting arm is the other fact adults misuse. In a CHAT analysis of spontaneous resolution, 82 of 194 children (42 percent) no longer met polysomnographic criteria after 7 months without surgery. Independent predictors included a lower baseline AHI and waist circumference under the 90th percentile. Symptomatic resolution was much less common than the number on the sleep study. Childhood OSA can recede as the airway grows or after the adenoids and tonsils come out. Adult OSA is not waiting on a growth spurt.

If you had adenotonsillectomy at age six and you are snoring at 46, you need a new evaluation. A resolved pediatric study does not cover an adult neck.

If it does not go away, what is treatment for?

Patil 2019 gives strong recommendations where the evidence is strongest: use PAP, compared with no therapy, for adults with OSA and excessive sleepiness; start PAP with home APAP or in-lab titration in people without significant comorbidities; continue with CPAP or APAP; give education at initiation. Conditional recommendations cover impaired sleep-related quality of life and comorbid hypertension. Those are reasons to treat a chronic disease, not claims that the disease will leave.

People ask whether they can “take a break” for a month and see. You can take a break. The airway will not have reconstructed itself in 30 days because you were curious. If a repeat study is the question, schedule the repeat study. If the question is whether you still need PAP after major weight loss or an operation, that is a legitimate retesting conversation. It is not the same as hoping the original diagnosis expires.

For adults in Westerville and the north Columbus metro, the practical next step is a visit that looks at the old study, the current symptoms, and whether anything that actually changes anatomy or weight has happened. Call (614) 898-9340. Bring prior reports. Do not stop a working treatment the week before the appointment in order to “show” the apnea. We already believe the diagnosis. We need to know what you are using now.

Sources

  1. Patil SP, Ayappa IA, Caples SM, Kimoff RJ, Patel SR, Harrod CG. Treatment of adult obstructive sleep apnea with positive airway pressure: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2019;15(2):335–343. https://jcsm.aasm.org/doi/10.5664/jcsm.7640
  2. Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(3):479–504. https://jcsm.aasm.org/doi/10.5664/jcsm.6506
  3. Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. 2000;284(23):3015–3021. https://doi.org/10.1001/jama.284.23.3015
  4. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193–1205. https://www.nejm.org/doi/full/10.1056/NEJMoa2404881
  5. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, for subcutaneous use. Prescribing information. OSA indication and SURMOUNT-OSA (Studies 5 and 6). https://pi.lilly.com/us/zepbound-uspi.pdf
  6. Marcus CL, Moore RH, Rosen CL, et al. A randomized trial of adenotonsillectomy for childhood sleep apnea. N Engl J Med. 2013;368(25):2366–2376. https://pmc.ncbi.nlm.nih.gov/articles/PMC3756808/
  7. Chervin RD, Ellenberg SS, Hou X, et al. Prognosis for spontaneous resolution of OSA in children. Chest. 2015;148(5):1204–1213. https://pmc.ncbi.nlm.nih.gov/articles/PMC4631037/
Mon to Fri 8:00 AM to 5:00 PM
Call (614) 898-9340